Inventiva receives FDA breakthrough therapy designation for lead drug candidate lanifibranor in NASH

Inventiva

12 October 2020 - Inventiva today announced that the U.S. FDA has granted breakthrough therapy designation to lanifibranor, the Company’s lead drug candidate, for the treatment of NASH. 

Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015.

Read Inventiva press release

Michael Wonder

Posted by:

Michael Wonder